- |||||||||| Journal: Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. (Pubmed Central) - Feb 21, 2025
Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks.
- |||||||||| LP0200 / LEO Pharma
Trial completion, Trial completion date, Trial primary completion date: A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (clinicaltrials.gov) - Jan 11, 2023
P1, N=108, Completed,
Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks. Recruiting --> Completed | Trial completion date: Nov 2022 --> Jul 2022 | Trial primary completion date: Nov 2022 --> Jul 2022
- |||||||||| LP0200 / LEO Pharma
Trial completion date, Trial primary completion date: A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (clinicaltrials.gov) - Feb 11, 2022
P1, N=134, Recruiting,
Recruiting --> Completed | Trial completion date: Nov 2022 --> Jul 2022 | Trial primary completion date: Nov 2022 --> Jul 2022 Trial completion date: Jan 2022 --> Nov 2022 | Trial primary completion date: Jan 2022 --> Nov 2022
|
